urogen.com - URGN Enterprise Value-to-Sales Ratio

Official company branding of UroGen Pharma (URGN)

The EV/Revenue multiple for UroGen Pharma Ltd. (URGN) reflects a trend where the current level sits around 6636.08. The company is shielded from trade wars due to the humanitarian status of its developments. Its operating model relies on fully outsourcing drug production to third-party contractors under strict standards, while UroGen Pharma Ltd. (URGN) is implementing a breakthrough thermosensitive gel for targeted chemotherapy delivery without surgery.

urogen.com (URGN): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

URGN (UroGen Pharma): analytical breakdowns and indicator data

- cash balance and cash flow data:
Fundamental company valuation:UroGen Pharma Ltd. URGN
Product sample of urogen.com

For UroGen Pharma Ltd. (URGN), Jelmyto sales volume and pipeline development drive market valuation amid high operating expenses. The EV/Sales history reflects the ratio of the total enterprise value, net of debt, to daily revenue. This metric allows for an assessment of asset monetization efficiency without distortions from leverage. The stability of the trend confirms the model's resilience, yet it masks the risks of a sharp correction. It is critical for investors to correlate this indicator with the expected FDA decision.

Competitor analysis for UroGen Pharma Ltd.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|EV/Sales Multiple BCAX|Personalis, Inc. - Company Value to Revenue Ratio|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio